Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol

Journal of Infectious Diseases

Volumn 201, Issue 8, 2010, Pages 1225-1231

  Srivastava, Shashikant ^a   Musuka, Sandirai ^a   Sherman, Carleton ^a   Meek, Claudia ^b   Leff, Richard ^b   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POPULATION STRUCTURE; PRIORITY JOURNAL; PUMP;

ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; ISONIAZID; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

EID: 77950195895     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651377     Document Type: Article

References (40)

1. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.
2. Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005;49:3178-3181.
3. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007;51:2329-2336.
4. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194-201.
5. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788.
6. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124.
7. Jayaram R Shandil RK, Gaonkar S, et al. Isoniazid pharmacokineticspharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004;48:2951-2957.
8. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, Sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582.
9. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. Pharmacokinetics- pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53:3197-3204.
10. Parsons LM, Salfinger M, Clobridge A, et al. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother 2005; 49: 2218-2225.
11. Colangeli R Helb D, Sridharan S, et al. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 2005; 55: 1829-1840.
12. Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther 2003; 1:141-155.
13. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-949.
14. O'Brien RJ. Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development? Am J Respir Crit Care Med 2002; 166:3-4.
15. Musuka S, Siyambalapitiyage Dona C, Gumbo T. Bad Drugs, Not Bad Bugs: Efflux-Pump Inhibition Abolishes the Selectivity of Standard Drugs against Tuberculosis (TB). In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2009. Abstract Al-605.
16. Lee CS, Gambertoglio JG, Brater DC, Benet LZ. Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther 1977;22:615-621.
17. Lee CS, Brater DC, Gambertoglio JG, Benet LZ. Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm 1980; 8:335-346.
18. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999;43:568-572.
19. Conte JE, Jr, Golden JA, Kipps J, Lin ET, Zurlinden E. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob Agents Chemother 2001;45:2891-2896.
20. Woods GL, Brown-Elliot BA, Desmond EP, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. Wayne, PA: Clinical and Laboratory Standards Institute, 2003.
21. D'Argenio DZ, Schumitzky A. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource. Los Angeles: University of Southern California, 1997.
22. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20:810-814.
23. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-15.
24. Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon PH, Godelle B. Role of mutator alleles in adaptive evolution. Nature 1997; 387:700-702.
25. Taddei F, Vulic M, Radman M, Matic I. Genetic variability and adaptation to stress. EXS 1997;83:271-290.
26. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952;65:523-546.
27. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M tuberculosis. N Engl J Med 2003; 349:1977-1978.
28. Spies FS, da Silva PE, Ribeiro MO, Rossetti ML, Zaha A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother 2008; 52:2947-2949.
29. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51:1534-1536.
30. Siddiqi N, Das R, Pathak N, et al. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 2004;32:109-111.
31. Jiang X, Zhang W, Zhang Y, et al. Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR Microb Drug Resist 2008; 14:7-11.
32. Morris RP, Nguyen L, Gatfield J, et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2005; 102: 12200-12205.
33. Ramon-Garcia S, Martin C, Ainsa JA, De RE. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother 2006; 57:252-259.
34. Louw GE, Warren RM, van Pittius NC, McEvoy CR, van Helden PD, Victor TC. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009;53:3181-3189.
35. Rad ME, Bifani P, Martin C, et al. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis 2003;9:838-845.
36. Nouvel LX, Kassa-Kelembho E, Dos VT, et al. Multidrug-resistant Mycobacterium tuberculosis, Bangui, Central African Republic. Emerg Infect Dis 2006;12:1454-1456.
37. Boshoff HI, Reed MB, Barry CE III, Mizrahi V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 2003;113:183-193.
38. Warner DF, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev 2006; 19:558-570.
39. Madison B, Robinson-Dunn B, George I, et al. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002; 40: 3976-3979.
40. Gupta P, Jadaun GPS, Das R, et al. Simultaneous ethambutol and isoniazid resistance in clinical isolates of Mycobacterium tuberculosis. Indian J Med Res 2006;123:125-130.